Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.

doi:10.1016/j.biopha.2016.04.019

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Jul 2016

Song Xuejiao, Zhang Lidan, Gao Tiantao, Ye Tinghong, Zhu Yongxia, Lei Qian, Feng Qiang, He Bing, Deng Hongxia, Yu Luoting

Abstract excerpt

EZH2 (Enhancer of zeste homolog 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is involved in repressing gene expression by methylating lysine 27 of histone H3 (H3K27) and regulates cell proliferation. EZH2 overexpression is implicated in tumorigenesis and has been a candidate oncogene in several tumor types. Recently, point mutations of EZH2 at Tyr641 and Ala677 were identified in...

Topics

Apoptosis
Benzamides
Cell Cycle Checkpoints
Cell Line, Tumor
Cell Proliferation
Cell Shape
Enhancer of Zeste Homolog 2 Protein
Histone Methyltransferases
Histone-Lysine N-Methyltransferase
Histones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Humans

Isoquinolines

Lymphoma

Lysine

Methylation

Mutation

Source

Open in PubMed

Identifiers

PMID: 27261606
DOI: 10.1016/j.biopha.2016.04.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.PMID 27261606Read ↗

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Semantic proximity Read ↗

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.Semantic proximity Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.Semantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.Semantic proximity Read ↗

Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

The biology of novel dual histone methyltransferase inhibitorsSemantic proximity Read ↗

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.